Literature DB >> 10597072

The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.

K N Boykin1, G B Zibari, D L Lilien, R W McMillan, D F Aultman, J C McDonald.   

Abstract

Each year at least 130,000 people in the United States are diagnosed with colorectal carcinoma. Approximately 14,000 of these patients will have liver metastases, and 20 per cent of these patients will die from these metastases. Surgical resection is the only possible chance for cure in patients with only intrahepatic metastases, and extrahepatic disease is a contraindication to glucose metabolism. Positron emission tomography (PET) allows the in vivo study of the uptake and use of glucose in human cells. Here, we review our experience with the use of PET imaging for the diagnosis and management of colorectal metastases of the liver. We conducted a retrospective chart review of 14 patients undergoing PET imaging for known or suspected hepatic metastases from colorectal carcinoma. Results of CT, magnetic resonance imaging, and PET images were compared with pathological specimens. CT scan identified 7 lesions, and PET identified 31 intrahepatic lesions. Of the 6 patients who underwent surgery, CT identified 4 (20%) and PET identified 17 (85%) of the 20 intrahepatic metastases histologically confirmed. The accuracy (number of lesions) of CT and PET was 20 per cent and 85 per cent, respectively. CT scans had a sensitivity (number of patients) of 50 per cent, and PET had a sensitivity of 100 per cent in patients undergoing surgical resection. PET imaging altered the management in 49 per cent of patients. Twenty-one per cent of patients had their surgery cancelled due to previously undiagnosed extrahepatic metastases. Twenty-one per cent of patients had negative CT scans and underwent surgery on the basis of their PET images, and all had histologically proven disease. One patient avoided a second-look laparotomy when PET revealed a lesion seen on CT to be false positive. PET is an ideal imaging modality to detect intra- and extrahepatic metastases from colorectal carcinomas and would aid in the surgical management of these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597072

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  12 in total

1.  Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer.

Authors:  H Furukawa; H Ikuma; A Seki; K Yokoe; S Yuen; T Aramaki; S Yamagushi
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

Review 2.  Restaging of colorectal cancer and PET/CT.

Authors:  Alev Çınar; Esra Arzu Gençoğlu; Meliha Korkmaz
Journal:  Ulus Cerrahi Derg       Date:  2013-06-01

3.  The role of positron emission tomography in colorectal carcinoma.

Authors:  Oussama M Nachar
Journal:  Ochsner J       Date:  2002

Review 4.  Current treatment for liver metastases from colorectal cancer.

Authors:  Lian-Xin Liu; Wei-Hui Zhang; Hong-Chi Jiang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

5.  Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.

Authors:  B Böhm; M Voth; J Geoghegan; H Hellfritzsch; A Petrovich; J Scheele; D Gottschild
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-06       Impact factor: 4.553

6.  Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases.

Authors:  Kenneth Coenegrachts; Frank De Geeter; Leon ter Beek; Natascha Walgraeve; Shandra Bipat; Jaap Stoker; Hans Rigauts
Journal:  Eur Radiol       Date:  2008-09-16       Impact factor: 5.315

7.  Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases.

Authors:  Chris M Schüssler-Fiorenza; David M Mahvi; John Niederhuber; Layton F Rikkers; Sharon M Weber
Journal:  J Gastrointest Surg       Date:  2004-02       Impact factor: 3.452

8.  Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer.

Authors:  Jose Manuel Llamas-Elvira; Antonio Rodríguez-Fernández; Javier Gutiérrez-Sáinz; Manuel Gomez-Rio; María Bellon-Guardia; Carlos Ramos-Font; Angel Custodio Rebollo-Aguirre; Dolores Cabello-García; Antonio Ferrón-Orihuela
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-29       Impact factor: 10.057

9.  The Use of PET-CT in the Assessment of Patients with Colorectal Carcinoma.

Authors:  Owen J O'Connor; Shanaugh McDermott; James Slattery; Dushyant Sahani; Michael A Blake
Journal:  Int J Surg Oncol       Date:  2011-07-03

Review 10.  The impact of functional imaging on radiation medicine.

Authors:  Nidhi Sharma; Donald Neumann; Roger Macklis
Journal:  Radiat Oncol       Date:  2008-09-15       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.